Tango Therapeutics Overview
Tango Therapeutics Target Price
See Tango Therapeutics's analyst price targets ($50) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$24.95
Average Target Price
$49.70
99.2% upside
99.2% upside10 analysts in the last 4 months
High: $69 | Low: $35
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-18 | H.C. WainwrightRobert Burns | $68 | 172.5% upside |  |
| 2026-08-12 | Guggenheim | $35 | 40.3% upside | |
| 2026-07-17 | Mizuho Securities | $40 | 60.3% upside | |
| 2026-06-29 | Canaccord Genuity | $46 | 84.4% upside | |
| 2026-06-25 | Jefferies | $60 | 140.5% upside | |
| 2026-06-09 | H.C. Wainwright | $66 | 164.5% upside | |
| 2026-06-09 | Canaccord Genuity | $42 | 68.3% upside | |
| 2026-06-08 | Leerink Partners | $69 | 176.6% upside | |
| 2026-06-08 | Mizuho SecuritiesJoseph Catanzaro | $36 | 44.3% upside | |
| 2026-06-08 | Wolfe Research | $35 | 40.3% upside | |
| 2026-05-15 | Mizuho SecuritiesJoseph Catanzaro | $30 | 20.2% upside | |
| 2026-05-14 | Piper Sandler | $24 |  3.8% downside | |
| 2026-05-14 | UBS | $55 | 120.4% upside | |
| 2026-05-14 | Wedbush | $33 | 32.3% upside | |
| 2026-05-14 | JefferiesMaury Raycroft | $27 | 8.2% upside | |
| 2026-04-27 | Stifel Nicolaus | $40 | 60.3% upside | |
| 2026-03-09 | Stifel NicolausLaura Prendergast | $24 | 3.8% downside | |
| 2026-03-05 | JefferiesMaury Raycroft | $18 | 27.9% downside | |
| 2026-02-23 | Mizuho Securities | $19 | 23.8% downside | |
| 2026-01-16 | Piper Sandler | $14 | 43.9% downside | |
| 2025-12-03 | Stifel Nicolaus | $15 | 39.9% downside | |
| 2025-10-24 | GuggenheimMichael Schmidt | $12 | 51.9% downside | |
| 2024-09-17 | Piper SandlerJoseph Catanzaro | $18 | 27.9% downside | |
| 2024-08-08 | WedbushRobert Driscoll | $13 | 47.9% downside | |
| 2024-05-28 | H.C. WainwrightRobert Burns | $13 | 47.9% downside | |